Effect of wound fluid on chemotherapy sensitivity of T24 bladder cancer cells with different enhancer of zeste homolog 2 status.

about

Effect of wound fluid on chemotherapy sensitivity of T24 bladder cancer cells with different enhancer of zeste homolog 2 status.

Item

http://www.wikidata.org/entity/Q41790109

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Effect of wound fluid on chemo ...... cer of zeste homolog 2 status.

@en

type

Item

label

Effect of wound fluid on chemo ...... cer of zeste homolog 2 status.

@en

prefLabel

Effect of wound fluid on chemo ...... cer of zeste homolog 2 status.

@en

P1476

Effect of wound fluid on chemo ...... cer of zeste homolog 2 status.

@en

P2093

Cheng Fu

http://www.w3.org/2001/XMLSchema#string

Huan Bi

http://www.w3.org/2001/XMLSchema#string

Li Guo

http://www.w3.org/2001/XMLSchema#string

Zetian Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system

EZH2 in Bladder Cancer, a Promising Therapeutic Target

Implementing Genome-Driven Oncology.

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.

IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway

Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer.

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.

P304

63258-63264

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.18791

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28968986

http://www.w3.org/2001/XMLSchema#string

P932

5609918

http://www.w3.org/2001/XMLSchema#string